New Drug Combos Outperform Disulfiram Against Lyme Persisters

Few questions in tick-borne medicine have generated as much confusion as the role of persister forms of Borrelia burgdorferi in persistent Lyme disease symptoms. The search for new drug combos that outperform disulfiram against Lyme persisters has now moved from anecdote into controlled laboratory investigation. In a 2020 study published in Antibiotics, researchers compared disulfiram with cefuroxime, clarithromycin, nitroxoline, furazolidone, nitazoxanide, and other agents against stationary-phase B. burgdorferi cultures enriched with persister forms. Their findings challenge the idea that disulfiram is a uniquely powerful anti-persister drug and point toward specific oral combinations that appear more effective in vitro.

Understanding the Persister Problem in Lyme Disease

Lyme disease is the most common vector-borne infection in the United States, with roughly thirty thousand cases reported each year to the Centers for Disease Control and Prevention. Many public health experts estimate that the true annual number of infections exceeds three hundred thousand. The infection is caused by members of the Borrelia burgdorferi sensu lato complex, a group of spirochetes that includes Borrelia burgdorferi in North America and Borrelia afzelii and Borrelia garinii in Europe. These organisms have evolved multiple strategies for surviving in tick vectors and in mammalian hosts.

Standard treatment for early localized or early disseminated Lyme disease typically relies on a two-to-four-week course of doxycycline, amoxicillin, or cefuroxime. Despite this approach, between ten and twenty percent of diagnosed patients continue to report persistent symptoms such as profound fatigue, musculoskeletal pain, joint pain, sleep disturbance, and neuropsychological impairment. When symptoms persist for more than six months after conventional treatment, the condition is often labeled post-treatment Lyme disease syndrome, or PTLDS. The reason why some patients remain ill is a topic of active scientific debate.

Several hypotheses have been proposed to explain persistent symptoms. Some researchers suggest that residual antigenic debris from dead spirochetes triggers ongoing inflammation. Others point to autoimmune responses or persistent infection that is difficult to identify with current diagnostic methods. The inability of standard Lyme tests to consistently detect all cases has further complicated clinical understanding. However, a growing body of laboratory and animal evidence indicates that a subpopulation of Borrelia cells can survive antibiotic exposure in a dormant or slow-growing state.

What Are Stationary-Phase Borrelia Persisters?

In the laboratory, Borrelia burgdorferi can be cultured in liquid medium until it reaches a stationary phase, usually after seven to ten days. At this point, the culture becomes enriched with forms that are not actively dividing in the same way as early logarithmic-phase spirochetes. These stationary-phase cultures contain planktonic spirochetes, round-body forms, and aggregated microcolonies. The microcolony and round-body forms are often described as antibiotic-tolerant persisters because they survive drug concentrations that kill actively growing cells.

Persisters are not always the result of classical genetic antibiotic resistance. In many cases, they represent a phenotypic state in which a bacterial cell reduces its metabolic activity and becomes less susceptible to drugs that require active cell wall synthesis, protein synthesis, or DNA replication. This phenomenon has been recognized in many bacterial species and is especially relevant for Borrelia because the organism can shift between different morphological forms. Doxycycline, a first-line Lyme drug, can induce round-body formation in vitro, which adds another layer of complexity to monotherapy.

The clinical significance of persister forms remains an area of active investigation. While they have not been definitively proven to cause PTLDS in humans, in vitro studies and some animal models suggest that these forms are more difficult to eradicate with conventional Lyme antibiotics. One mouse model study showed that Borrelia persisters not killed by current Lyme antibiotics could be eradicated by a three-drug combination containing daptomycin, doxycycline, and a cephalosporin. This finding validated the concept that drug combinations targeting persisters may be necessary for more complete bacterial clearance.

Why Single-Antibiotic Therapy Often Falls Short

Many patients and clinicians have observed that single-antibiotic therapy with doxycycline or amoxicillin may not fully resolve symptoms in a subset of Lyme disease cases. Laboratory studies help explain one possible reason. Conventional Lyme antibiotics are most effective against actively growing spirochetes, but they frequently fail to eradicate stationary-phase aggregated forms and round bodies. In the persister model, this leaves a reservoir of viable organisms that can potentially regrow after the antibiotic pressure is removed.

The limitations of single-agent therapy are not unique to Lyme disease. Persistent infections such as tuberculosis, Q fever, and biofilm-associated infections often require prolonged combination therapy to prevent relapse. The challenge with Lyme disease is that oral antibiotics used in current practice have not been optimized against Borrelia persister forms. Researchers have therefore screened existing drugs to find agents that can be repurposed as persister-active treatments.

Daptomycin-based combinations have shown strong activity in vitro and in one mouse model, but daptomycin is an intravenous drug that is expensive and inconvenient for many patients. This has motivated researchers to identify oral alternatives that can target persisters more effectively than standard regimens. Disulfiram became one candidate because early in vitro screening suggested it had activity against growing Borrelia. However, the newer combination study shows that its activity against stationary-phase persisters is weaker than previously assumed.

Why Disulfiram Was Considered a Candidate for Lyme Persisters

Disulfiram is a synthetic organosulfur drug that has been used for decades to discourage alcohol consumption in people with alcohol use disorder. Its active metabolite, diethyldithiocarbamate, inhibits aldehyde dehydrogenase, which leads to accumulation of acetaldehyde and produces an unpleasant reaction when alcohol is consumed. Beyond this established use, disulfiram has attracted interest as an antimicrobial agent. It has shown some activity against Mycobacterium tuberculosis, Pseudomonas aeruginosa biofilms, and growing forms of Borrelia burgdorferi.

A 2016 drug screening identified disulfiram as effective against the growing form of Borrelia burgdorferi. In that study, the minimum inhibitory concentration was reported as 0.625 micromolar, and the minimum bactericidal concentration was 1.25 micromolar. At a concentration of 1.25 micromolar, disulfiram was reported to inhibit 99.8 percent of borrelial growth in a stationary-phase culture compared with untreated controls. These results generated considerable enthusiasm, especially because disulfiram is an oral drug that could be repurposed for Lyme disease.

Subsequent animal research showed that most mice treated with high-dose disulfiram at 75 milligrams per kilogram for five days cleared infection from many tissues as measured by quantitative PCR. However, lower doses of ten milligrams per kilogram did not achieve clearance. Several case reports described patients with relapsing neurological Lyme symptoms who improved during disulfiram therapy lasting six to eighteen weeks. These encouraging reports led some clinicians to prescribe disulfiram empirically for patients with persistent Lyme symptoms.

The problem with the early disulfiram data is that the Bac-Titer-Glo assay used in the original screening may not reliably detect metabolically inactive persister cells. The assay measures ATP as a marker of viability, but dormant or slow-growing persisters may have very low ATP levels and may be missed. In addition, the previous stationary-phase inhibition results did not include subculture studies to determine whether the bacteria could regrow after drug exposure. The newer study by Alvarez-Manzo and colleagues directly addressed these gaps using a viability assay that detects both live and dead cells in planktonic and aggregated forms.

Disulfiram Toxicity and Clinical Limitations

Disulfiram is not a benign medication. Its use is associated with significant adverse reactions, including peripheral neuropathy, headache, anxiety, concentration difficulties, and in some cases suicidal thoughts. Psychiatric side effects can be especially problematic in patients who already experience cognitive and mood symptoms as part of persistent Lyme disease. The drug also interacts with alcohol and with many other medications, which imposes lifestyle restrictions and monitoring burdens.

Some patients treated with disulfiram have reported improvements in neurological Lyme symptoms, but these clinical observations are difficult to interpret. Improvement could result from the antimicrobial effect of disulfiram, an anti-inflammatory effect, regression to the mean, or other concurrent treatments. Without controlled clinical trials, it is impossible to know whether disulfiram-specific activity is responsible for the improvement. The new laboratory evidence suggests that disulfiram is not particularly potent against stationary-phase Borrelia persisters compared with other oral agents.

This has important implications for patient safety. If disulfiram is no better than cefuroxime against persisters and carries substantial neurological and psychiatric toxicity, then its routine use as a Lyme persister drug becomes harder to justify. The search for alternatives is therefore not only a scientific question but also a clinical safety priority. The good news is that the 2020 combination study identified two oral drugs, clarithromycin and nitroxoline, that appear to outperform disulfiram in the laboratory.

New Drug Combos Outperform Disulfiram Against Lyme Persisters in the Laboratory

The study by Alvarez-Manzo, Zhang, Shi, and Zhang evaluated disulfiram as a single drug and in two-drug and three-drug combinations against stationary-phase Borrelia burgdorferi strain N40. The researchers used a SYBR Green I and propidium iodide staining assay to calculate bacterial survival rates based on green and red fluorescence. This method can measure viability in both planktonic cells and aggregated microcolonies, making it more sensitive than traditional counting chambers that mainly count free-floating cells.

At clinically relevant peak serum concentrations, known as Cmax, cefuroxime achieved a survival rate of 36.8 percent. Nitroxoline and clarithromycin produced survival rates of 37.5 percent and 41.1 percent respectively, making them statistically equivalent to cefuroxime as single agents. Disulfiram, by contrast, left 46.3 percent of bacteria viable, which was almost ten percentage points worse than cefuroxime. This was an early signal that disulfiram is not a superior persister drug at achievable concentrations.

The most striking findings emerged when the researchers compared drug combinations. The two-drug combination of cefuroxime plus clarithromycin reduced bacterial survival to 25.9 percent. Cefuroxime plus nitroxoline achieved 27.5 percent survival. Both combinations were significantly more active than the cefuroxime plus disulfiram combination, which left 41.7 percent of bacteria viable. In other words, replacing disulfiram with clarithromycin or nitroxoline produced a clear improvement in bacterial killing in the laboratory model.

These results matter because two-drug combinations are easier to administer than three-drug regimens. If an oral two-drug combination can match or exceed a disulfiram-containing regimen, it may offer a more practical path forward. The data also reinforce the principle that drug selection against persisters cannot be based solely on activity against growing spirochetes. A drug may look impressive in logarithmic-phase cultures but fail when tested against the stationary-phase forms that likely matter in persistent infection.

Two-Drug New Drug Combos Outperform Disulfiram Against Lyme Persisters at Cmax

The Cmax experiments were designed to simulate the peak concentration of each drug in human serum after oral ingestion. This is a more clinically relevant condition than using an arbitrarily high concentration that may never be achieved in a patient. When tested at Cmax, the two-drug combination of cefuroxime plus clarithromycin was significantly better than the standard cefuroxime plus doxycycline control. The cefuroxime plus nitroxoline combination showed a similar advantage.

The difference between cefuroxime plus clarithromycin and cefuroxime plus disulfiram was substantial. Survival dropped from 41.7 percent with disulfiram to 25.9 percent with clarithromycin. The combination with nitroxoline reduced survival to 27.5 percent. These findings suggest that both clarithromycin and nitroxoline contribute meaningful anti-persister activity when added to a beta-lactam anchor drug such as cefuroxime.

It is also noteworthy that disulfiram-containing two-drug combinations were generally less active than cefuroxime-containing two-drug combinations. The only exception was disulfiram plus furazolidone. This pattern indicates that disulfiram may not be the best partner for cefuroxime or doxycycline in targeting stationary-phase Borrelia. Clarithromycin and nitroxoline appear to be more logical candidates for further development.

Two-drug regimens are particularly attractive because they reduce pill burden, lower the risk of drug interactions, and may be better tolerated over the longer treatment durations sometimes used for persistent Lyme symptoms. The laboratory data do not prove that two-drug therapy is sufficient for patients, but they justify additional animal and clinical investigation of cefuroxime plus clarithromycin and cefuroxime plus nitroxoline.

Three-Drug New Drug Combos Outperform Disulfiram Against Lyme Persisters in Viability Assays

The study also evaluated three-drug combinations that included furazolidone or nitazoxanide alongside cefuroxime and a third agent. When disulfiram was the third agent, the results were unimpressive. Cefuroxime plus disulfiram plus nitazoxanide left 23.9 percent of bacteria viable. Cefuroxime plus disulfiram plus furazolidone left 25.1 percent viable. Only cefuroxime plus disulfiram plus nitroxoline managed to reduce survival to 12.5 percent.

When disulfiram was replaced with clarithromycin or nitroxoline, the three-drug combinations became significantly more active. Cefuroxime plus clarithromycin plus furazolidone reduced survival to 6.6 percent, while cefuroxime plus nitroxoline plus furazolidone reduced survival to 1.7 percent. Both results were statistically superior to the disulfiram-containing counterpart. The combination with clarithromycin plus nitazoxanide achieved 5.0 percent survival, and the nitroxoline plus nitazoxanide combination achieved 11.0 percent survival.

These data show that the choice of the persister-active drug within a three-drug regimen has a major impact on bacterial killing. Disulfiram was consistently the weakest option in these comparisons. Clarithromycin and nitroxoline demonstrated stronger activity against stationary-phase forms when combined with furazolidone or nitazoxanide. This is a key reason why the study authors concluded that new drug combos outperform disulfiram against Lyme persisters.

The positive control in these experiments was the combination of cefuroxime, doxycycline, and daptomycin. This regimen produced zero percent viability in repeated tests and served as a benchmark for complete eradication in vitro. Although the oral combinations did not always reach zero percent survival in the initial viability assay, several of them prevented regrowth in subculture, which is a more stringent measure of bactericidal effect.

Subculture Evidence That New Drug Combos Outperform Disulfiram Against Lyme Persisters

A viability assay provides a snapshot of bacterial survival immediately after drug exposure, but it does not reveal whether the surviving cells can regrow. Subculture studies address this limitation by removing the drugs and placing the treated bacteria in fresh growth medium for several weeks. If no regrowth occurs, the drug combination is considered capable of eradicating the persister population under the conditions tested.

In the subculture experiments, cefuroxime plus disulfiram plus nitazoxanide regrew after twenty-one days. Cefuroxime plus disulfiram plus furazolidone also regrew. These results show that despite reducing bacterial viability in the short term, the disulfiram-containing combinations did not fully eliminate the persister reservoir. Only cefuroxime plus disulfiram plus nitroxoline prevented regrowth in the subculture assay, along with the positive control containing daptomycin.

In contrast, all four combinations containing clarithromycin or nitroxoline prevented regrowth after three weeks. Cefuroxime plus clarithromycin plus nitazoxanide, cefuroxime plus nitroxoline plus nitazoxanide, cefuroxime plus clarithromycin plus furazolidone, and cefuroxime plus nitroxoline plus furazolidone all showed no regrowth. This is a crucial finding because it indicates that the superior killing observed in the viability assay translated into more complete eradication in the subculture model.

The discrepancy between the disulfiram combinations and the clarithromycin or nitroxoline combinations underscores the importance of subculture testing. A drug can look promising in a short viability assay yet fail to prevent relapse when drug pressure is removed. The subculture data argue strongly that clarithromycin and nitroxoline deserve further attention as potential replacements for disulfiram in Lyme persister regimens.

How Clarithromycin and Nitroxoline Work Against Borrelia Persisters

Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is generally considered a bacteriostatic drug, meaning that it slows or stops bacterial growth rather than directly killing cells. However, macrolides can be bactericidal against certain bacteria under specific conditions. The activity of clarithromycin against Borrelia has been recognized for many years, but its role in treating persistent forms is now being reevaluated.

The 2020 study reported a minimum inhibitory concentration for clarithromycin of 0.04 micrograms per milliliter, which was lower than that of cefuroxime and doxycycline. This low MIC indicates that clarithromycin has potent activity against growing Borrelia. Its usefulness against stationary-phase persisters may also stem from its ability to penetrate cells and tissues, including the central nervous system. Borrelia burgdorferi can invade various tissues and may reside in protected niches, so tissue penetration is an important consideration.

Nitroxoline is an older urinary antiseptic antibiotic that has been used in Europe for urinary tract infections. It has recently attracted renewed interest because of its activity against biofilm-associated infections and multidrug-resistant Enterobacteriaceae. Nitroxoline chelates metal ions and has multiple mechanisms of action, including inhibition of bacterial adhesion and disruption of biofilm formation. These properties may be especially relevant for Borrelia, which can form biofilm-like microcolonies in stationary-phase cultures.

At Cmax, nitroxoline produced a survival rate of 37.5 percent as a single agent, which was equivalent to cefuroxime and superior to disulfiram. When combined with cefuroxime and furazolidone, nitroxoline achieved the lowest survival rate of any oral regimen tested at 1.7 percent. This suggests that nitroxoline has a meaningful anti-persister effect that is amplified when combined with a cell wall-active beta-lactam and another persister drug such as furazolidone.

Cefuroxime as an Anchor Drug in Combination Therapy

Cefuroxime is a second-generation cephalosporin that inhibits bacterial cell wall synthesis. It is one of the standard oral antibiotics for early Lyme disease and has good activity against growing Borrelia burgdorferi. In the 2020 study, cefuroxime achieved the best single-drug survival rate at Cmax, 36.8 percent. This makes it a logical anchor drug for combination regimens aimed at persister forms.

The use of cefuroxime in combinations is not meant to imply that it eradicates persisters on its own. Rather, cefuroxime likely kills actively growing spirochetes and may weaken the cell wall structure of some persister forms, making them more vulnerable to other agents. The addition of clarithromycin or nitroxoline provides a second mechanism of action that targets different bacterial processes. Adding furazolidone or nitazoxanide provides a third mechanism, which may be necessary to prevent regrowth.

Furazolidone is a nitrofuran antibiotic that damages DNA and other macromolecules. Nitazoxanide is a thiazolide antiparasitic drug with activity against anaerobic bacteria and some protozoa. Both drugs have shown anti-persister activity in the stationary-phase Borrelia model. When combined with cefuroxime and clarithromycin or nitroxoline, they helped produce the strong subculture results observed in the study.

Why Disulfiram Underperformed in This Model

The underperformance of disulfiram in the 2020 study likely reflects several factors. First, the stationary-phase culture was specifically enriched with persister forms, which are metabolically less active than the logarithmic-phase cultures used in the original disulfiram screening. Disulfiram may have stronger activity against actively growing spirochetes but weaker activity against dormant or slow-growing persister cells. Second, the Cmax for disulfiram is quite low, around 0.4 micrograms per milliliter, which limits the concentration that can be achieved after oral dosing.

Third, the SYBR Green I and propidium iodide assay used in this study detects viability in both planktonic and microcolony forms. Earlier assays that relied on ATP production or counting chambers may have underestimated the number of surviving aggregated cells. The subculture results confirmed that disulfiram-containing combinations often left a reservoir of viable bacteria capable of regrowth. This is consistent with the hypothesis that disulfiram is not a reliable persister eradicator at clinically achievable concentrations.

It is important to acknowledge that disulfiram may still have value in some clinical contexts, especially for patients who have failed other therapies and who are carefully monitored for side effects. However, the laboratory evidence no longer supports the view that disulfiram is uniquely effective against Borrelia persisters. Safer and more effective oral options may exist, and the findings with clarithromycin and nitroxoline provide a strong rationale for further study.

Patient Impact and the Search for Safer Oral Regimens

For patients with persistent Lyme symptoms, the search for better treatments is urgent. Many people experience years of fatigue, cognitive dysfunction, joint pain, and neurological symptoms that impair their ability to work and maintain relationships. The lack of a universally effective regimen has led patients and clinicians to try many off-label therapies, including disulfiram, herbal tinctures, and unconventional antibiotic combinations. The new data on clarithromycin and nitroxoline offer a more scientifically grounded direction.

Clarithromycin is widely available as an oral antibiotic and has a well-characterized safety profile, although it can cause gastrointestinal upset, taste disturbance, and QT prolongation in susceptible individuals. It has been used for prolonged courses in other persistent infections such as Mycobacterium avium complex, suggesting that longer-term administration may be feasible under medical supervision. Nitroxoline is not available in the United States but is marketed in several European countries, where it has been used for urinary tract infections.

Nitroxoline’s lack of availability in the United States is a practical limitation. The study authors noted that Europe has a higher estimated prevalence of Lyme disease than the United States, with many cases caused by Borrelia afzelii and Borrelia garinii. If nitroxoline shows activity against these European species in future studies, it could be repurposed in countries where the drug is already licensed. For U.S. patients, clarithromycin-based combinations may be more immediately accessible.

It is critical to emphasize that laboratory findings do not automatically translate into clinical benefit. The stationary-phase culture model is an artificial system that does not capture the full complexity of human infection, including immune responses, tissue penetration, biofilm architecture in joints or brain, and Borrelia strain variation. Patients should not self-prescribe clarithromycin, nitroxoline, furazolidone, or nitazoxanide based on this study alone. Any off-label use should be guided by a physician who can weigh risks and benefits.

What Patients and Clinicians Should Understand About These Findings

The most important message from the 2020 study is that disulfiram is not the strongest anti-persister option in the laboratory when compared with clarithromycin and nitroxoline. This challenges several high-profile claims that disulfiram is a breakthrough cure for persistent Lyme disease. Patients who have been told that disulfiram is uniquely effective should understand that more recent comparative data do not support that conclusion.

At the same time, the study does not prove that clarithromycin or nitroxoline combinations are cures for PTLDS. The experiments were conducted in vitro using a single Borrelia burgdorferi strain. They used stationary-phase cultures enriched with persister forms, which is a useful but incomplete model. The subculture experiments showed prevention of regrowth under defined laboratory conditions, but this is not the same as eradicating infection from a human host.

Clinicians should view these results as hypothesis-generating. They justify further investigation of cefuroxime plus clarithromycin and cefuroxime plus nitroxoline in animal models and, eventually, controlled human studies. They also provide a basis for reconsidering the widespread empiric use of disulfiram, given its toxicity and the availability of potentially more effective alternatives. Shared decision-making with patients should include an honest discussion of the limited evidence base.

Clinical Limitations and What These Findings Do Not Prove

The laboratory model used in the study has several important limitations. Stationary-phase Borrelia cultures grown in BSK-H medium do not replicate the conditions inside a human joint, brain, heart, or peripheral nerve. The persister forms in culture may differ from those that arise during infection. Drug concentrations at the site of infection can vary widely and may be lower or higher than serum Cmax values depending on tissue perfusion, protein binding, and local pH.

The study used a single strain, Borrelia burgdorferi N40. Results may not apply equally to other Borrelia species, including Borrelia afzelii, Borrelia garinii, Borrelia mayonii, and others. Different species and strains can have different susceptibilities to antibiotics and may vary in their ability to form persisters. This is especially relevant for Europe, where the genospecies distribution differs from that in North America.

Subculture studies measure regrowth under optimal laboratory conditions, but they cannot account for the immune system. In human infection, the immune response may help clear residual bacteria that survive antibiotic exposure. Conversely, immune evasion by Borrelia may allow persisters to survive despite a competent host response. The interplay between host immunity and antibiotic treatment is difficult to model in vitro and remains a major gap in Lyme persister research.

The study did not evaluate gene expression, molecular targets, or resistance mechanisms. It also did not assess whether the treatments selected for resistant mutants or caused morphological changes that could influence pathogenicity. Future studies should examine whether clarithromycin or nitroxoline combinations induce specific resistance pathways and whether the persister forms that survive treatment remain infectious or capable of causing disease.

The Role of Biofilms, Immune Modulation, and Host Response

Borrelia burgdorferi can form biofilm-like structures in vitro, and these structures have been proposed as one reason for antibiotic tolerance. Biofilms create a protective matrix that limits drug penetration and shelters slow-growing cells. Nitroxoline has anti-biofilm activity against some bacteria, which may contribute to its strong performance in the stationary-phase Borrelia model. Clarithromycin also has immunomodulatory properties that may affect inflammation independently of its antibacterial effect.

It is possible that some clinical benefit reported with macrolides in Lyme disease arises not only from direct bacterial killing but also from modulation of the host inflammatory response. Persistent symptoms such as fatigue and cognitive dysfunction may be driven in part by neuroinflammation. If a drug reduces inflammation while also suppressing bacterial regrowth, it could provide dual benefit. However, this hypothesis requires direct testing in clinical studies.

The immune system plays a central role in controlling Borrelia infection, but it can also contribute to tissue damage. Antigenic debris from dead spirochetes may trigger ongoing inflammation even after viable organisms are eliminated. This means that antimicrobial therapy alone may not fully resolve symptoms in every patient. An integrated approach that addresses infection, inflammation, and host recovery may be necessary for meaningful clinical improvement.

Future Directions for Lyme Persister Treatment Research

The logical next step is to test the most promising combinations in animal models of Lyme borreliosis. Mouse models can help determine whether cefuroxime plus clarithromycin or cefuroxime plus nitroxoline eradicates persisters in tissues and whether the combinations are safe over the durations needed. Animal studies can also evaluate different dosing schedules, tissue penetration, and the potential for relapse after treatment is stopped.

Ex vivo models may provide an intermediate step between pure in vitro culture and whole-animal studies. For example, researchers can assess spirochete growth in cell lines or tissue explants to evaluate how drug combinations perform in a more complex environment. Such models can help prioritize regimens for more expensive animal testing. They may also reveal whether Borrelia survives within fibroblasts, endothelial cells, or other protected niches.

Nitroxoline’s availability in Europe makes it a particularly interesting candidate for clinical research in regions with high Lyme disease incidence. Studies should include Borrelia afzelii and Borrelia garinii to determine whether the drug’s activity extends beyond the North American N40 strain. If nitroxoline demonstrates safety and efficacy in European Lyme disease models, it could be repurposed relatively quickly because it is already licensed for urinary tract infections.

Clarithromycin is widely available and has been used for long-term therapy in other chronic infections. However, its use in Lyme disease requires careful attention to cardiac safety, drug interactions, and the potential for Clostridioides difficile infection. Any prolonged antibiotic regimen must be balanced against the risks of disrupting the gut microbiome and selecting for resistant organisms. The goal is not simply to prescribe more antibiotics, but to identify the shortest effective course that prevents relapse.

Toward More Personalized Treatment of Persistent Lyme Disease

Persistent Lyme disease is unlikely to have a single universal cure. Different patients may have different dominant mechanisms driving their symptoms, including persistent infection, immune dysregulation, tissue damage, or a combination of these factors. Biomarkers that distinguish active infection from post-infectious inflammation would greatly improve treatment decisions. Until such biomarkers exist, clinicians must rely on clinical judgment, patient history, and the emerging science of Borrelia persisters.

Combination therapy may prove to be an important component of treatment for some patients, especially those with objective evidence of persistent infection or those who relapse after standard therapy. The choice of drugs should be guided by laboratory evidence, but it must also account for the patient’s overall health, organ function, and tolerance. Clarithromycin and nitroxoline are not miracle drugs, but they represent a more rational starting point than disulfiram based on current in vitro data.

It is reasonable to expect that future treatment protocols will move away from reliance on a single antibiotic and toward carefully designed multi-drug regimens that target different bacterial forms. The concept is similar to tuberculosis therapy, where multiple drugs with different mechanisms are used to prevent the emergence of resistance and to sterilize different bacterial populations. For Lyme disease, this may mean combining a cell wall-active beta-lactam with a protein synthesis inhibitor and a drug that disrupts persister-specific pathways.

Conclusion

The 2020 study by Alvarez-Manzo and colleagues provides important evidence that new drug combos outperform disulfiram against Lyme persisters in a stationary-phase Borrelia burgdorferi culture model. Disulfiram performed poorly as a single agent at clinically relevant concentrations, with a survival rate of 46.3 percent compared with 36.8 percent for cefuroxime. Replacing disulfiram with clarithromycin or nitroxoline in two-drug and three-drug combinations produced significantly lower bacterial survival and prevented regrowth in subculture studies.

Clarithromycin and nitroxoline are not yet proven treatments for persistent Lyme disease, and the limitations of in vitro research must be acknowledged. However, the findings raise serious questions about the continued enthusiasm for disulfiram as a Lyme persister drug. They also provide a strong rationale for prioritizing clarithromycin and nitroxoline in future animal and clinical studies. Patients and clinicians should view these results with cautious optimism, recognizing that laboratory models are only one step in the long process of developing safer and more effective treatments.

The broader lesson is that Borrelia persisters require combination strategies, not single wonder drugs. Standard Lyme antibiotics such as doxycycline and cefuroxime have important roles, but they are not sufficient against all bacterial forms. The search for oral persister-active agents is ongoing, and the 2020 study moves that search forward by identifying clarithromycin and nitroxoline as superior alternatives to disulfiram. With further research, these combinations may eventually lead to more effective options for people living with persistent Lyme symptoms.